Cardurion is a Massachusetts-based biotechnology company that develops and commercializes novel therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion was founded in 2017. Cardurion's headquarters is located in Boston, ... Cardurion's President & CEO, Peter S. Lawrence, currently has an approval
rating of 88%. Cardurion's primary competitors are Ardelyx, CinCor & XyloCor.
There have been no acquisitions found related to Cardurion
Recent investment data cannot be found related to Cardurion